These discrepancies and controversies regarding METTL3 in GBM may depend on variable m6A reader protein and research contexts such as the origin of tumor sample, compensatory genetic mutation, and epigenetic influence of GSC cells in distinctive growth backgrounds. This evidence concerns the gene METTL3 and glioblastoma.